Clinical trial · Observational
Prediction of Individual Radiosensitivity During Radiotherapy for Breast Cancer Patients
Prediction of Individual Radiosensitivity During Radiotherapy for Breast Cancer Patients, the Role of Genetic and Inflammatory Markers
NCT05566613CI-TRIAL-00061202SENSunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Non-randomized clinical cohort study investigating if single nucleotide polymorphism (SNP) or inflammatory markers can predict radiosensitivity in breast cancer patients receiving radiotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Radiation Tolerance | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Acute radiation dermatitis grading criteria
- timeFrame
- Before and during treatment and after one year
- description
- Acute radiation dermatitis grading criteria according to the Radiation Therapy Oncology Group. Minimum value 1 and maximum value 4, higher value means a worse outcome
Secondary outcomes (5)
- measure
- Quality of life (QoL)
- timeFrame
- Before and during treatment and after one year
- description
- Quality of life determined by European Organisation for Research and Treatment of Cancer questionnaire QLQ-C30
- measure
- Breast cancer specific Quality of life (QoL)
- timeFrame
- Before and during treatment and after one year
- description
- Quality of life determined by European Organisation for Research and Treatment of Cancer questionnaire QLQ-BR23
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Patients receiving adjuvant radiotherapy for breast cancer 2,67 Gy x 15 (or a radio biologically equivalent dose) * \> 18 years * Being able to read and understand patient information in Swedish * Signed informed consent Exclusion criteria: * Ongoing infection * Fever \>37,9 degrees Celsius * Unable to follow study protocol
References
Publications (0)
Data not yet available
No reference posted for this study.